Abstract
In comparison to other classes of cell surface receptors, the medicinal chemistry at P2X (ligand-gated ion channels) and P2Y (G protein-coupled) nucleotide receptors has been relatively slow to develop. Recent effort to design selective agonists and antagonists based on a combination of library screening, empirical modification of known ligands, and rational design have led to the introduction of potent antagonists of the P2X1 (derivatives of pyridoxal phosphates and suramin), P2X3 (A-317491), P2X7 (derivatives of the isoquinoline KN-62), P2Y1 (nucleotide analogues MRS 2179 and MRS 2279), P2Y2 (thiouracil derivatives such as AR-C126313), and P2Y12 (nucleotide / nucleoside analogues AR-C69931X and AZD6140) receptors. A variety of native agonist ligands (ATP, ADP, UTP, UDP, and UDP-glucose) are currently the subject of structural modification efforts to improve selectivity. MRS2365 is a selective agonist for P2Y1 receptors. The dinucleotide INS 37217 potently activates the P2Y2 receptor. UTP-g-S and UDP-b-S are selective agonists for P2Y2 / P2Y4 and P2Y6 receptors, respectively. The current knowledge of the structures of P2X and P2Y receptors, is derived mainly from mutagenesis studies. Site-directed mutagenesis has shown that ligand recognition in the human P2Y1 receptor involves individual residues of both the TMs (3, 5, 6, and 7), as well as EL 2 and 3. The binding of the negatively-charged phosphate moiety is dependent on positively charged lysine and arginine residues near the exofacial side of TMs 3 and 7.
Keywords: pyrimidine nucleotide (p2) receptors, ligand-gated ion channels, a-317491
Current Topics in Medicinal Chemistry
Title: Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors
Volume: 4 Issue: 8
Author(s): Kenneth A. Jacobson, Stefano Costanzi, Michihiro Ohno, Bhalchandra V. Joshi, Pedro Besada, Bin Xu and Susanna Tchilibon
Affiliation:
Keywords: pyrimidine nucleotide (p2) receptors, ligand-gated ion channels, a-317491
Abstract: In comparison to other classes of cell surface receptors, the medicinal chemistry at P2X (ligand-gated ion channels) and P2Y (G protein-coupled) nucleotide receptors has been relatively slow to develop. Recent effort to design selective agonists and antagonists based on a combination of library screening, empirical modification of known ligands, and rational design have led to the introduction of potent antagonists of the P2X1 (derivatives of pyridoxal phosphates and suramin), P2X3 (A-317491), P2X7 (derivatives of the isoquinoline KN-62), P2Y1 (nucleotide analogues MRS 2179 and MRS 2279), P2Y2 (thiouracil derivatives such as AR-C126313), and P2Y12 (nucleotide / nucleoside analogues AR-C69931X and AZD6140) receptors. A variety of native agonist ligands (ATP, ADP, UTP, UDP, and UDP-glucose) are currently the subject of structural modification efforts to improve selectivity. MRS2365 is a selective agonist for P2Y1 receptors. The dinucleotide INS 37217 potently activates the P2Y2 receptor. UTP-g-S and UDP-b-S are selective agonists for P2Y2 / P2Y4 and P2Y6 receptors, respectively. The current knowledge of the structures of P2X and P2Y receptors, is derived mainly from mutagenesis studies. Site-directed mutagenesis has shown that ligand recognition in the human P2Y1 receptor involves individual residues of both the TMs (3, 5, 6, and 7), as well as EL 2 and 3. The binding of the negatively-charged phosphate moiety is dependent on positively charged lysine and arginine residues near the exofacial side of TMs 3 and 7.
Export Options
About this article
Cite this article as:
Jacobson A. Kenneth, Costanzi Stefano, Ohno Michihiro, Joshi V. Bhalchandra, Besada Pedro, Xu Bin and Tchilibon Susanna, Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors, Current Topics in Medicinal Chemistry 2004; 4 (8) . https://dx.doi.org/10.2174/1568026043450961
DOI https://dx.doi.org/10.2174/1568026043450961 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Synthesis, Structural Study and Anticancer Activity Evaluation of Emodin Derivatives Containing Conjugative Groups
Medicinal Chemistry Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry p53: A Guide to Apoptosis
Current Cancer Drug Targets Bioactive Molecule-loaded Drug Delivery Systems to Optimize Bone Tissue Repair
Current Protein & Peptide Science Computer Simulation of the Effects of Contrast Protocols on Aortic Signal Intensity on Magnetic Resonance Angiograms
Current Medical Imaging Patent Selections
Recent Patents on Cardiovascular Drug Discovery Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design Vascular Smooth Muscle Relaxation by a Lectin from Pisum arvense: Evidences of Endothelial NOS Pathway
Protein & Peptide Letters Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells in Cartilage Regeneration
Current Stem Cell Research & Therapy Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine